🚀 VC round data is live in beta, check it out!
Sun Pharma Valuation Multiples
Discover revenue and EBITDA valuation multiples for Sun Pharma and similar public comparables like Alnylam Pharmaceuticals, Bayer, CSL, Lonza Group and more.
Sun Pharma Overview
About Sun Pharma
Sun Pharmaceuticals Industries Ltd is India's generic pharmaceutical manufacturing company. The company’s substantial markets are the U.S. and India to make up the majority of revenue. The remaining is spread across both emerging and developed markets. In addition to generics, the company also produces and distributes name-brand formulas to specific geographies. It maintains manufacturing and research and development facilities globally to serve its markets but is majorly based in India.
Founded
1993
HQ
Employees
19.3K
Website
Sectors
Financials (LTM)
EV
$41B
Sun Pharma Financials
Sun Pharma reported last 12-month revenue of $6B and EBITDA of $2B.
In the same LTM period, Sun Pharma generated $5B in gross profit, $2B in EBITDA, and $1B in net income.
Revenue (LTM)
Sun Pharma P&L
In the most recent fiscal year, Sun Pharma reported revenue of $6B and EBITDA of $2B.
Sun Pharma expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $6B | XXX | $6B | XXX | XXX | XXX |
| Gross Profit | $5B | XXX | $4B | XXX | XXX | XXX |
| Gross Margin | 80% | XXX | 70% | XXX | XXX | XXX |
| EBITDA | $2B | XXX | $2B | XXX | XXX | XXX |
| EBITDA Margin | 29% | XXX | 29% | XXX | XXX | XXX |
| EBIT Margin | 25% | XXX | 24% | XXX | XXX | XXX |
| Net Profit | $1B | XXX | $1B | XXX | XXX | XXX |
| Net Margin | 21% | XXX | 22% | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Sun Pharma Stock Performance
Sun Pharma has current market cap of $43B, and enterprise value of $41B.
Market Cap Evolution
Sun Pharma's stock price is $18.01.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $41B | $43B | -0.7% | XXX | XXX | XXX | $0.56 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialSun Pharma Valuation Multiples
Sun Pharma trades at 6.5x EV/Revenue multiple, and 22.0x EV/EBITDA.
EV / Revenue (LTM)
Sun Pharma Financial Valuation Multiples
As of April 18, 2026, Sun Pharma has market cap of $43B and EV of $41B.
Equity research analysts estimate Sun Pharma's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Sun Pharma has a P/E ratio of 33.0x.
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $43B | XXX | $43B | XXX | XXX | XXX |
| EV (current) | $41B | XXX | $41B | XXX | XXX | XXX |
| EV/Revenue | 6.5x | XXX | 6.7x | XXX | XXX | XXX |
| EV/EBITDA | 22.0x | XXX | 22.8x | XXX | XXX | XXX |
| EV/EBIT | 26.0x | XXX | 27.6x | XXX | XXX | XXX |
| EV/Gross Profit | 8.1x | XXX | 9.5x | XXX | XXX | XXX |
| P/E | 33.0x | XXX | 31.9x | XXX | XXX | XXX |
| EV/FCF | 45.8x | XXX | 31.6x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Sun Pharma Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Sun Pharma Margins & Growth Rates
Sun Pharma's revenue in the last 12 month grew by 11%.
Sun Pharma's revenue per employee in the last FY averaged $0.3M, while opex per employee averaged $0.2M for the same period.
Sun Pharma's rule of 40 is 41% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Sun Pharma's rule of X is 58% (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
Sun Pharma Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 11% | XXX | 3% | XXX | XXX | XXX |
| EBITDA Margin | 29% | XXX | 29% | XXX | XXX | XXX |
| EBITDA Growth | 12% | XXX | 3% | XXX | XXX | XXX |
| Rule of 40 | — | XXX | 41% | XXX | XXX | XXX |
| Bessemer Rule of X | — | XXX | 58% | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.3M | XXX | XXX | XXX |
| Opex per Employee | — | XXX | $0.2M | XXX | XXX | XXX |
| S&M Expenses to Revenue | — | XXX | 12% | XXX | XXX | XXX |
| G&A Expenses to Revenue | — | XXX | 7% | XXX | XXX | XXX |
| R&D Expenses to Revenue | 6% | XXX | 6% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 48% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Sun Pharma Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Sun Pharma | XXX | XXX | XXX | XXX | XXX | XXX |
| Alnylam Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| Bayer | XXX | XXX | XXX | XXX | XXX | XXX |
| CSL | XXX | XXX | XXX | XXX | XXX | XXX |
| Lonza Group | XXX | XXX | XXX | XXX | XXX | XXX |
| Sandoz | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Sun Pharma M&A Activity
Sun Pharma acquired XXX companies to date.
Last acquisition by Sun Pharma was on XXXXXXXX, XXXXX. Sun Pharma acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Sun Pharma
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialSun Pharma Investment Activity
Sun Pharma invested in XXX companies to date.
Sun Pharma made its latest investment on XXXXXXXX, XXXXX. Sun Pharma invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Sun Pharma
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Sun Pharma
| When was Sun Pharma founded? | Sun Pharma was founded in 1993. |
| Where is Sun Pharma headquartered? | Sun Pharma is headquartered in India. |
| How many employees does Sun Pharma have? | As of today, Sun Pharma has over 19K employees. |
| Is Sun Pharma publicly listed? | Yes, Sun Pharma is a public company listed on National Stock Exchange of India. |
| What is the stock symbol of Sun Pharma? | Sun Pharma trades under SUNPHARMA ticker. |
| When did Sun Pharma go public? | Sun Pharma went public in 1995. |
| Who are competitors of Sun Pharma? | Sun Pharma main competitors are Alnylam Pharmaceuticals, Bayer, CSL, Lonza Group. |
| What is the current market cap of Sun Pharma? | Sun Pharma's current market cap is $43B. |
| What is the current revenue of Sun Pharma? | Sun Pharma's last 12 months revenue is $6B. |
| What is the current revenue growth of Sun Pharma? | Sun Pharma revenue growth (NTM/LTM) is 11%. |
| What is the current EV/Revenue multiple of Sun Pharma? | Current revenue multiple of Sun Pharma is 6.5x. |
| Is Sun Pharma profitable? | Yes, Sun Pharma is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Sun Pharma? | Sun Pharma's last 12 months EBITDA is $2B. |
| What is Sun Pharma's EBITDA margin? | Sun Pharma's last 12 months EBITDA margin is 29%. |
| What is the current EV/EBITDA multiple of Sun Pharma? | Current EBITDA multiple of Sun Pharma is 22.0x. |
| What is the current FCF of Sun Pharma? | Sun Pharma's last 12 months FCF is $886M. |
| What is Sun Pharma's FCF margin? | Sun Pharma's last 12 months FCF margin is 14%. |
| What is the current EV/FCF multiple of Sun Pharma? | Current FCF multiple of Sun Pharma is 45.8x. |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.